Connect with us

Toshiba Launches Low Power Consumption Brushed DC Motor Driver IC With Popular Pin-assignment HSOP8 Package

Published

on

Reading Time: 3 minutes

TOKYO–(BUSINESS WIRE)–Toshiba
Electronic Devices & Storage Corporation
(“Toshiba”) has
launched “TB67H450FNG,” the latest addition to its line-up of brushed DC
motor driver ICs. The new product with a maximum rating of 50V/3.5A[1]
drives motors with a wide range of operating voltage. It also offers a
small HSOP8 surface mount package with a popular pin-assignment that
enhances the product sourcing possibility. Mass production starts today.

The new IC can drive brushed motors with a power supply ranging from
4.5V to 44V. It supports wide range of applications that includes, USB
powered, battery powered, and industrial 12-36V devices. TB67H450FNG
also has 3.5A current driving capability that can be used in
applications such as robot vacuum cleaners, refrigerators and other home
appliances actuators, office equipment, ATM machines, and many others.

To meet demand for lower power consumption, Toshiba has also optimized
the TB67H450FNG standby current consumption with a new power supply
circuit that allows the stop mode to move into standby mode
automatically and to turn off the VCC regulator for internal circuit
operation. This helps OA equipment and home appliances to cut energy
consumption and improves the battery life of battery powered devices.

Housed in a small surface-mount type HSOP8 pin package, the IC achieves
space saving and yet good heat dissipation through the package thermal
pad design.

Key Features

  • Wide range of operating voltages: from 4.5V to 44V for large-current
    drive devices
  • Low standby current consumption: 1 μA (max) @VM=24V, Ta=25°C
  • Small 8-pin surface mount package HSOP8 with a popular pin-assignment
    and with bottom side E-pad to enhance thermal dissipation

Applications

Industrial equipment, including OA equipment and banking terminals; home
appliances, including robot vacuum cleaners; battery powered devices
(electronic locks and small household robots); and devices using 5V USB
power supplies

 

Main Specifications

Part number   TB67H450FNG
Supply voltage (operating range) 4.5V to 44V

Output voltage/current
(Absolute maximum rating)

50V/3.5A
Number of H-bridge channels 1ch
Motor to apply DC Brushed motor
Output on-resistance (upper + lower) 0.6Ω (typ.)@VM=24V, Ta=25℃
Safety function Over current detection, thermal shut down, and under voltage lockout
Package

HSOP8
(Size: 4.9mm×6.0mm)

Other features Current consumption in standby mode: 1 μA or less

Constant-current control

(constant-current PWM control)

Support forward/reverse/stop control

Stock Check & Purchase  

Buy
Online

 

Note:
[1] Actual driven motor current depends on the use
environment and such factors as ambient temperature and power supply
voltage.

For more information about the new product, please visit:
https://toshiba.semicon-storage.com/ap-en/product/linear/motordriver/detail.TB67H450FNG.html

To check the availability of the new product at online distributors,
please visit:
https://toshiba.semicon-storage.com/ap-en/buy/stockcheck.TB67H450FNG.html

*Company names, product names, and service names may be trademarks of
their respective companies.

Customer Inquiries:
System Devices Marketing Dept.II
Tel:
+81-3-3457-3332
https://toshiba.semicon-storage.com/ap-en/contact.html

Information in this document, including product prices and
specifications, content of services and contact information, is current
on the date of the announcement but is subject to change without prior
notice.

About Toshiba Electronic Devices & Storage Corporation

Toshiba Electronic Devices & Storage Corporation combines the vigor of a
new company with the wisdom of experience. Since becoming an independent
company in July 2017, we have taken our place among the leading general
devices companies, and offer our customers and business partners
outstanding solutions in discrete semiconductors, system LSIs and HDD.

Our 22,000 employees around the world share a determination to maximize
the value of our products, and emphasize close collaboration with
customers to promote co-creation of value and new markets. We look
forward to building on annual sales now surpassing 800-billion yen (US$7
billion) and to contributing to a better future for people everywhere.
Find
out more about us at https://toshiba.semicon-storage.com/ap-en/top.html

Contacts

Media Inquiries:
Toshiba Electronic Devices & Storage
Corporation
Digital Marketing Department
Chiaki Nagasawa
Tel:
+81-3-3457-4963
semicon-NR-mailbox@ml.toshiba.co.jp

Cannabis

One Year of Medical Cannabis in the UK, Data by Grow Biotech

Published

on

Photo source: southeusummit.com

 

The 1st of November 2019 will mark the one year anniversary of the legalisation of medical cannabis in the United Kingdom. A year after Charlotte Caldwell’s tireless campaign to obtain life-saving medication for her son Billy catapulted medical cannabis onto the public agenda, the cost of prescriptions has dropped substantially while the number of scripts written has increased, but more needs to be done before it can be more widely offered by the National Health Service (NHS).

The average price of a month’s supply of medical cannabis imported through Logist has dropped from £750 to £550, reducing the average monthly prescription cost by 27%, while the average price per gram has also fallen by 25%. The reduction in cost is a combination of increased volume (meaning the costs associated with importing products is lower per prescription) and the increased availability of different products.

The type of medical specialist consultants writing prescriptions for medical cannabis has also diversified to include pain, oncology and neurology. There has also been a broadening in the delivery method for medical cannabis requested by specialist consultants to include different cannabis oils, pills and flowers, which is largely a result of the greater range of products available. Since February, Logist has imported approximately 1.5kg of flower to the UK.

The vast majority of medical cannabis has made its way to the UK thanks to Logist, a joint-venture formed between specials importer IPS Pharma, and Grow Biotech, the UK’s leading medical cannabis market access specialists.

Timeline of Events

  • 1st November 2018 – New regulations introduced, which allowed for the import and prescription of cannabis-based medicines
  • 14 February 2019 – The first bulk import of medical cannabis in the UK and first patients to receive medication from Logist
  • May 2019 – EU based bio-pharmaceutical company MGC Pharma appoints Logist
  • August 2019 – NICE publish interim report on medical cannabis
  • August 2019 – American medical cannabis giant Columbia Care announces that it will fund and provide medicine for clinical trials in the UK
  • September 2019– Leading Canadian company Aurora appoints IPS Pharma and Grow Biotech as importer and distributor for the UK market
  • September 2019 – Medical cannabis consultant informs Logist that a patient is no longer using opioids to manage their condition following treatment with medical cannabis

Looking forward to the near future, Chief Operating Officer of Grow Biotech, Hari Guliani, said, “Over the next twelve months we expect the UK’s medical community as a whole to take on the challenge of understanding how cannabis might help their patients. We are expecting leading consultants to publish papers on the impact they have seen on their patients, as well as evidence gathered through MHRA-approved trials. This will significantly improve the data available to regulators, policymakers and NICE.”

At present, it is only available on the NHS in extremely limited circumstances and is only obtainable through a prescription written by a specialist consultant in the private sector. NICE (The National Institute of Health Care Excellence) has advised that more clinical trials need to be undertaken in the UK and overall costs of medication need to be reduced before medical cannabis can be prescribed by NHS consultants. However, new medical trials are now underway and prices associated with the import of medical cannabis are falling dramatically, giving hope to the thousands of patients who are still struggling to access life-changing medication.

Another major change which cannot be overlooked is funding for the UK’s young medical cannabis industry. Ben Langley, Chief Executive Officer of Grow Biotech explained that, “We have seen a massive increase in funding for UK businesses operating within the medical cannabis space, especially from North America. In addition to the £5m Grow Biotech has raised over the last two years, there have been notably well received fundraises for Emmac Life Sciences PLC (£11m raised in March 2019) and for Oxford Cannabinoid Therapeutics ($10m in April 2019). This trend is likely to accelerate as European medical cannabis gradually establishes itself as an attractive asset class for global capital and European equity exchanges start to open their doors to cannabis companies.

Both Ben Langley and Hari Guliani are available for comment and interview.

 

SOURCE Grow Biotech

Continue Reading

Cannabis

GNCC Capital, Inc. – Pending Transaction

Published

on

 

GNCC Capital, Inc. (OTC: GNCP) (“The Company” or “GNCC”) advises that the new Board of Directors is in the process of consummating a further transaction in the Cannabis Sector and in South Africa.

Given that this is a related party transaction; they are awaiting ratification from an Independent party.

Upon consummation of this transaction; the new GNCC Directors will actively engage with shareholders. This decision was taken given that this transaction materially affects the size and scope of the Company’s South African Cannabis interests.

We reiterate that both Ms. Allen and Mr. Cox have recognized the need to; and have committed to expend the next two to three weeks in shareholder engagement. This is to ensure that all shareholders and investors become familiar with the Company’s new business operations, opportunities, Licensing and the Cannabis Industry in South Africa.

Forward-Looking Statements:-This press release may contain forward-looking statements. The words “believe,” “expect,” “should,” “intend,” “estimate,” “projects,” variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. These forward-looking statements are based upon the Company’s current expectations and are subject to a number of risks, uncertainties and assumptions. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. Among the important factors that could cause actual results to differ significantly from those expressed or implied by such forward-looking statements are risks that are detailed in the Company’s filings, which are on file with the OTC Markets Group.

SOURCE GNCC Capital, Inc.

Continue Reading

Cannabis

Empower Clinics Provides Corporate Updates Highlighting Triple Digit Patient Growth and Subsidiary Sun Valley Health Launches New Modalities and Patient Services

Published

on

 

EMPOWER CLINICS INC. (CSE: CBDT) (OTC: EPWCF) (Frankfurt 8EC) (“Empower” or the “Company“), a vertically integrated and growth-oriented CBD life sciences company, a multi-state operator of medical health & wellness clinics, a CBD product producer and operator of an extraction facility in Oregon, is pleased to announce it is launching seven new modalities and services for patients in the Sun Valley Health clinics commencing Monday October 14th, 2019.

The Company also has patient visits in corporate clinics increase by triple digits, with September 2019 patients seen increasing by 307% to 1,884 versus September 2018 with 614 patients seen.

“The tremendous year-over-year increase in patient visits is a testament to the operating strengths and patient management demonstrated by our clinic team members, each and every day,” said Steven McAuley, CEO of Empower. “Their passion for patient wellbeing and the use of numerous communication tools ensures world-class service is provided throughout the entire patient journey.”

As part of the Company’s continued expansion of our health & wellness clinic model, we have already set up retail CBD product sales in-clinic, and now we have launched expanded physician based services.

New Modalities and Services

  • Physician’s CBD Enhanced Massage, Acupuncture, or Cupping Sessions
  • CBD-Cannabis-Supplement Consumption & Coaching Consultation
  • Introduction to Alternative Health and Cannabinoid Therapies by a Physician
  • Comprehensive Naturopathic Patient Analysis & Consultation
  • Dietary Antigen Testing, Physician Consultation/Action Plan, & Concierge Blood Draw
  • Neurotransmitter (urine) Profile & Physician Consultation/Action Plan
  • Spectracell Micronutrient Test & Physician Consultation/Action Plan

“By offering our new suite of laboratory testing, alternative health consulting, and CBD therapies we are able to address the needs of our current patients and serve the community outside of cannabis that are seeking alternative health care,” states Dustin Klein, Director & VP Business Development. “Incorporating our new modalities, high quality vitamins, supplements, and CBD products into our network of clinics is a natural progression toward our goal of becoming the nation’s premier alternative healthcare provider.”

Additional UPDATES

  • New Modalities and Patient Services The Company continues to see patient visits in corporate clinics increase by triple digits, with September 2019 patients seen increasing by 307% to 1,884 over July 2018 614 patients seen.

  • Sun Valley Health Franchise Sun Valley Health www.sunvalleyhealth.com has been actively participating in various franchise and cannabis expos in St. LouisChicago and Houston to market the Sun Valley Health franchise program, attracting numerous qualified candidates for available territory locations. The Company has accepted many applications and has provided the Franchise Disclosure Document (FDD) to qualified applicants in anticipation of completing the first initial territory sales.

 

SOURCE Empower Clinics Inc.

Continue Reading

Trending Online

Grassnews is a news publishing website which digests / hand picks the latest news about the cannabis industry, and serves them to you daily.

Contact us: pressroom@grassnews.net

© Grassnews.net 2019 - part of PICANTE Media. All rights reserved. Registered in Romania under Proshirt SRL, Company number: 2134306, EU VAT ID: RO21343605. Office address: Blvd. 1 Decembrie 1918 nr.5, Targu Mures, Romania